Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

Interactions Between Signaling Pathways

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

Negative Regulator Molecules

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

High throughput screening aids clinical decision-making in refractory acute myeloid leukaemia.

Cancer reports (Hoboken, N.J.)·2024

Same author

SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization.

Oncogene·2014

Same author

Adolescent conceptions of the homeland: A cross-cultural study.

Journal of youth and adolescence·2013

Same author

Regulatory feedback loop between TP73 and TRIM32.

Cell death & disease·2013

Same author

Late mortality after hematopoietic SCT for a childhood malignancy.

Bone marrow transplantation·2013

Same author

Targeting the p53-family in cancer and chemosensitivity: triple threat.

Current drug targets·2010

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.

L M S Lau¹, J K Nugent, X Zhao

¹Division of Hematology/Oncology, Department of Paediatrics, Hospital for Sick Children, University of Toronto, Ontario, Canada.

|August 19, 2007

Summary

Nutlin-3 triggers cell death independently of p53 by targeting p73. This small molecule inhibitor disrupts the p73-HDM2 interaction, enhancing p73

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Experiment Videos

Last Updated: Jul 13, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Area of Science:

Molecular Biology
Cancer Research
Cell Death Mechanisms

Background:

Nutlin-3 is a small molecule inhibitor known to activate p53 by disrupting its association with HDM2.
p53-null cancer cells exhibit Nutlin-3-induced cell death, suggesting a p53-independent mechanism.
p73, a homolog of p53, also induces apoptosis and is negatively regulated by HDM2.

Purpose of the Study:

To investigate whether p73 mediates Nutlin-3-induced apoptosis in p53-null cells.
To elucidate the mechanism of Nutlin-3 action in the context of p53 inactivation.

Main Methods:

Assessed the interaction between p73 and HDM2 in p53-null cells treated with Nutlin-3.
Measured the transcriptional activity of p73 and the expression of its target genes (noxa, puma, p21).
Utilized siRNA to knock down p73 and evaluated the effect on Nutlin-3-induced apoptosis.
Determined the impact of Nutlin-3 on TAp73alpha protein levels and half-life.

Main Results:

Nutlin-3 inhibited the binding of the proapoptotic p73 isoform TAp73alpha to HDM2 in p53-null cells.
This dissociation led to increased p73 transcriptional activity, upregulating target genes noxa, puma, and p21.
Nutlin-3 treatment enhanced apoptosis, which was partially rescued by p73 knockdown.
Nutlin-3 increased TAp73alpha protein levels and prolonged its half-life.

Conclusions:

Nutlin-3 disrupts the endogenous p73-HDM2 interaction, enhancing p73 stability and proapoptotic activity.
This p73-dependent mechanism provides a rationale for using Nutlin-3 in human tumors with p53 inactivation.